Display options
Cite
Rosager AM, Dahlrot RH, Sørensen MD, et al. The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients. J Neuropathol Exp Neurol. 2021;doi: 10.1093/jnen/nlab124.
Rosager, A. M., Dahlrot, R. H., Sørensen, M. D., Bangsø, J. A., Hansen, S., & Kristensen, B. W. (2021). The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients. Journal of neuropathology and experimental neurology, . https://doi.org/10.1093/jnen/nlab124
Rosager, Ann Mari, et al. "The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients." Journal of neuropathology and experimental neurology vol. (2021). doi: https://doi.org/10.1093/jnen/nlab124
Rosager AM, Dahlrot RH, Sørensen MD, Bangsø JA, Hansen S, Kristensen BW. The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients. J Neuropathol Exp Neurol. 2021 Dec 07; doi: 10.1093/jnen/nlab124. Epub 2021 Dec 07. PMID: 34875075.
Copy Download .nbib Format: NLM
Share it on

J Neuropathol Exp Neurol. 2021 Dec 07; doi: 10.1093/jnen/nlab124. Epub 2021 Dec 07.

The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients.

Journal of neuropathology and experimental neurology

Ann Mari Rosager, Rikke H Dahlrot, Mia D Sørensen, Julie A Bangsø, Steinbjørn Hansen, Bjarne W Kristensen

Affiliations

  1. From the Department of Pathology, Odense University Hospital, Odense, Denmark (AMR, MDS, JAB, BWK); Department of Clinical Research, University of Southern Denmark, Odense, Denmark (AMR, RHD, MDS, JAB, SH, BWK); Department of Oncology, Odense University Hospital, Odense, Denmark (RHD, SH); Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark (BWK); Department of Clinical Medicine and Biotech Research and Innovation Center (BRIC), University of Copenhagen, Copenhagen, Denmark (BWK).

PMID: 34875075 DOI: 10.1093/jnen/nlab124

Abstract

Patients with IDH-wildtype glioblastoma (GBM) generally have a poor prognosis. However, there is an increasing need of novel robust biomarkers in the daily clinico-pathological setting to identify and support treatment in patients who become long-time survivors. Jumonji domain-containing protein 6 (JMJD6) is involved in epigenetic regulation of demethylation of histones and has been associated with GBM aggressiveness. We investigated the expression and prognostic potential of JMJD6 tumor fraction score in 184 IDH-wildtype GBMs. Whole-slides were double-stained with an antibody against JMJD6 and an exclusion-cocktail consisting of 4 antibodies (CD31, SMA, CD45, and Iba-1), enabling evaluation of tumor cells only. Stainings were quantified with a combined software- and scoring-based approach. For comparison, IDH-mutated WHO grade II, III and IV astrocytic gliomas were also stained, and the JMJD6 tumor fraction score increased with increasing WHO grade, although not significantly. In multivariate analysis including age, gender, performance status and post-surgical treatment high JMJD6 tumor fraction score was associated with longer overall survival in IDH-wildtype GBMs (p = 0.03), but the effect disappeared when MGMT promoter status was included (p = 0.34). We conclude that JMJD6 is highly expressed in IDH-wildtype GBM but it has no independent prognostic value.

© 2021 American Association of Neuropathologists, Inc. All rights reserved.

Keywords: Brain tumor; Glioma; Jumonji domain-containing protein 6; Microglia; Prognostic; Tumor stem cell

Publication Types